Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Cell-free circulating epimarks in cancer monitoring.

Duforestel M, Briand J, Bougras-Cartron G, Heymann D, Frenel JS, Vallette FM, Cartron PF.

Epigenomics. 2020 Jan;12(2):145-155. doi: 10.2217/epi-2019-0170. Epub 2020 Jan 9.

PMID:
31916450
2.

Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma.

Rabé M, Dumont S, Álvarez-Arenas A, Janati H, Belmonte-Beitia J, Calvo GF, Thibault-Carpentier C, Séry Q, Chauvin C, Joalland N, Briand F, Blandin S, Scotet E, Pecqueur C, Clairambault J, Oliver L, Perez-Garcia V, Nadaradjane A, Cartron PF, Gratas C, Vallette FM.

Cell Death Dis. 2020 Jan 6;11(1):19. doi: 10.1038/s41419-019-2200-2.

3.

Epigenetic protein complexes: the adequate candidates for the use of a new generation of epidrugs in personalized and precision medicine in cancer.

Cartron PF, Cheray M, Bretaudeau L.

Epigenomics. 2020 Jan;12(2):171-177. doi: 10.2217/epi-2019-0169. Epub 2019 Dec 18.

PMID:
31849240
4.

Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation.

Briand J, Nadaradjane A, Bougras-Cartron G, Olivier C, Vallette FM, Cartron PF.

Clin Epigenetics. 2019 Nov 14;11(1):159. doi: 10.1186/s13148-019-0759-1.

5.

Glyphosate Primes Mammary Cells for Tumorigenesis by Reprogramming the Epigenome in a TET3-Dependent Manner.

Duforestel M, Nadaradjane A, Bougras-Cartron G, Briand J, Olivier C, Frenel JS, Vallette FM, Lelièvre SA, Cartron PF.

Front Genet. 2019 Sep 27;10:885. doi: 10.3389/fgene.2019.00885. eCollection 2019.

6.

Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma.

Georges S, Calleja LR, Jacques C, Lavaud M, Moukengue B, Lecanda F, Quillard T, Gabriel MT, Cartron PF, Baud'huin M, Lamoureux F, Heymann D, Ory B.

Oncotarget. 2018 Nov 6;9(87):35726-35741. doi: 10.18632/oncotarget.26284. eCollection 2018 Nov 6.

7.

miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker.

Nadaradjane A, Briand J, Bougras-Cartron G, Disdero V, Vallette FM, Frenel JS, Cartron PF.

Mol Ther Nucleic Acids. 2018 Dec 7;13:642-650. doi: 10.1016/j.omtn.2018.09.007. Epub 2018 Sep 13.

8.

Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality?

Brown HK, Tellez-Gabriel M, Cartron PF, Vallette FM, Heymann MF, Heymann D.

Drug Discov Today. 2019 Mar;24(3):763-772. doi: 10.1016/j.drudis.2018.11.017. Epub 2018 Nov 26. Review.

9.

Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer.

Vallette FM, Olivier C, Lézot F, Oliver L, Cochonneau D, Lalier L, Cartron PF, Heymann D.

Biochem Pharmacol. 2019 Apr;162:169-176. doi: 10.1016/j.bcp.2018.11.004. Epub 2018 Nov 9. Review.

10.

Epigenetic Metalloenzymes.

Blanquart C, Linot C, Cartron PF, Tomaselli D, Mai A, Bertrand P.

Curr Med Chem. 2019;26(15):2748-2785. doi: 10.2174/0929867325666180706105903. Review.

PMID:
29984644
11.

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.

Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, Pallandre JR, Bouard A, Balland J, Tirole C, Adotevi O, Hendrick E, Herfs M, Cartron PF, Borg C, Hervouet E.

Oncoimmunology. 2018 Feb 1;7(5):e1423170. doi: 10.1080/2162402X.2017.1423170. eCollection 2018.

12.

Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma.

Hervouet E, Peixoto P, Delage-Mourroux R, Boyer-Guittaut M, Cartron PF.

Clin Epigenetics. 2018 Feb 9;10:17. doi: 10.1186/s13148-018-0450-y. eCollection 2018. Review.

13.

Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia.

Bagacean C, Tempescul A, Le Dantec C, Bordron A, Mohr A, Saad H, Olivier V, Zdrenghea M, Cristea V, Cartron PF, Douet-Guilbert N, Berthou C, Renaudineau Y.

Oncotarget. 2017 Aug 9;8(39):65699-65716. doi: 10.18632/oncotarget.20081. eCollection 2017 Sep 12.

14.

Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death.

Moserova I, Truxova I, Garg AD, Tomala J, Agostinis P, Cartron PF, Vosahlikova S, Kovar M, Spisek R, Fucikova J.

Oncoimmunology. 2016 Nov 18;6(1):e1258505. doi: 10.1080/2162402X.2016.1258505. eCollection 2017.

15.

The phosphorylation of Metaxin 1 controls Bak activation during TNFα induced cell death.

Petit E, Cartron PF, Oliver L, Vallette FM.

Cell Signal. 2017 Jan;30:171-178. doi: 10.1016/j.cellsig.2016.11.008. Epub 2016 Nov 12.

16.

Specific Inhibition of DNMT3A/ISGF3γ Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth.

Cheray M, Pacaud R, Nadaradjane A, Oliver L, Vallette FM, Cartron PF.

Theranostics. 2016 Aug 25;6(11):1988-1999. eCollection 2016.

17.

The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent.

Brenner C, Luciani J, Bizet M, Ndlovu M, Josseaux E, Dedeurwaerder S, Calonne E, Putmans P, Cartron PF, Defrance M, Fuks F, Deplus R.

Oncotarget. 2016 Sep 13;7(37):58939-58952. doi: 10.18632/oncotarget.10624.

18.

Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation.

Myrianthopoulos V, Cartron PF, Liutkevičiūtė Z, Klimašauskas S, Matulis D, Bronner C, Martinet N, Mikros E.

Eur J Med Chem. 2016 May 23;114:390-6. doi: 10.1016/j.ejmech.2016.02.043. Epub 2016 Feb 23.

PMID:
27049577
19.

Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.

Pacaud R, Cheray M, Nadaradjane A, Vallette FM, Cartron PF.

Theranostics. 2015 Jan 1;5(1):12-22. doi: 10.7150/thno.8799. eCollection 2015.

20.

Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness.

Cheray M, Nadaradjane A, Bonnet P, Routier S, Vallette FM, Cartron PF.

Epigenomics. 2014 Jun;6(3):267-75. doi: 10.2217/epi.14.18.

PMID:
25111481
21.

New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.

Gueugnon F, Cartron PF, Charrier C, Bertrand P, Fonteneau JF, Gregoire M, Blanquart C.

Oncotarget. 2014 Jun 30;5(12):4504-15.

22.

DNMT3L interacts with transcription factors to target DNMT3L/DNMT3B to specific DNA sequences: role of the DNMT3L/DNMT3B/p65-NFκB complex in the (de-)methylation of TRAF1.

Pacaud R, Sery Q, Oliver L, Vallette FM, Tost J, Cartron PF.

Biochimie. 2014 Sep;104:36-49. doi: 10.1016/j.biochi.2014.05.005. Epub 2014 Jun 18.

PMID:
24952347
23.

Metaxins 1 and 2, two proteins of the mitochondrial protein sorting and assembly machinery, are essential for Bak activation during TNF alpha triggered apoptosis.

Cartron PF, Petit E, Bellot G, Oliver L, Vallette FM.

Cell Signal. 2014 Sep;26(9):1928-34. doi: 10.1016/j.cellsig.2014.04.021. Epub 2014 May 2.

PMID:
24794530
24.

The DNMT1/PCNA/UHRF1 disruption induces tumorigenesis characterized by similar genetic and epigenetic signatures.

Pacaud R, Brocard E, Lalier L, Hervouet E, Vallette FM, Cartron PF.

Sci Rep. 2014 Mar 18;4:4230. doi: 10.1038/srep04230.

25.

High hydrostatic pressure induces immunogenic cell death in human tumor cells.

Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, Fialova A, Sojka L, Cartron PF, Houska M, Rob L, Bartunkova J, Spisek R.

Int J Cancer. 2014 Sep 1;135(5):1165-77. doi: 10.1002/ijc.28766. Epub 2014 Feb 20.

26.

Control of glioma cell death and differentiation by PKM2-Oct4 interaction.

Morfouace M, Lalier L, Oliver L, Cheray M, Pecqueur C, Cartron PF, Vallette FM.

Cell Death Dis. 2014 Jan 30;5:e1036. doi: 10.1038/cddis.2013.561.

27.

Identification of TET1 Partners That Control Its DNA-Demethylating Function.

Cartron PF, Nadaradjane A, Lepape F, Lalier L, Gardie B, Vallette FM.

Genes Cancer. 2013 May;4(5-6):235-41. doi: 10.1177/1947601913489020.

28.

Antioxidants delay clinical signs and systemic effects of ENU induced brain tumors in rats.

Hervouet E, Staehlin O, Pouliquen D, Debien E, Cartron PF, Menanteau J, Vallette FM, Olivier C.

Nutr Cancer. 2013;65(5):686-94. doi: 10.1080/01635581.2013.789541.

PMID:
23859036
29.

Specific inhibition of one DNMT1-including complex influences tumor initiation and progression.

Cheray M, Pacaud R, Nadaradjane A, Vallette FM, Cartron PF.

Clin Epigenetics. 2013 Jun 28;5(1):9. doi: 10.1186/1868-7083-5-9.

30.

Epigenetic regulation of estrogen signaling in breast cancer.

Hervouet E, Cartron PF, Jouvenot M, Delage-Mourroux R.

Epigenetics. 2013 Mar;8(3):237-45. doi: 10.4161/epi.23790. Epub 2013 Jan 30. Review.

31.

HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression.

Cartron PF, Blanquart C, Hervouet E, Gregoire M, Vallette FM.

Mol Oncol. 2013 Jun;7(3):452-63. doi: 10.1016/j.molonc.2012.11.004. Epub 2012 Dec 21.

32.

DNA methylation and apoptosis resistance in cancer cells.

Hervouet E, Cheray M, Vallette FM, Cartron PF.

Cells. 2013 Jul 18;2(3):545-73. doi: 10.3390/cells2030545.

33.

Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme.

Cartron PF, Loussouarn D, Campone M, Martin SA, Vallette FM.

Cell Death Dis. 2012 Nov 15;3:e421. doi: 10.1038/cddis.2012.150.

34.

Kinetics of DNA methylation inheritance by the Dnmt1-including complexes during the cell cycle.

Hervouet E, Nadaradjane A, Gueguen M, Vallette FM, Cartron PF.

Cell Div. 2012 Feb 20;7:5. doi: 10.1186/1747-1028-7-5.

35.

Folate supplementation limits the tumourigenesis in rodent models of gliomagenesis.

Cartron PF, Hervouet E, Debien E, Olivier C, Pouliquen D, Menanteau J, Loussouarn D, Martin SA, Campone M, Vallette FM.

Eur J Cancer. 2012 Oct;48(15):2431-41. doi: 10.1016/j.ejca.2012.01.002. Epub 2012 Feb 8.

PMID:
22325970
36.

ABT-737 and/or folate reverse the PDGF-induced alterations in the mitochondrial apoptotic pathway in low-grade glioma patients.

Debien E, Hervouet E, Gautier F, Juin P, Vallette FM, Cartron PF.

Clin Epigenetics. 2011 Aug;2(2):369-381. Epub 2011 May 15.

37.

Proximity ligation in situ assay for monitoring the global DNA methylation in cells.

Hervouet E, Hulin P, Vallette FM, Cartron PF.

BMC Biotechnol. 2011 Apr 6;11:31. doi: 10.1186/1472-6750-11-31.

38.

Bax activation by engagement with, then release from, the BH3 binding site of Bcl-xL.

Gautier F, Guillemin Y, Cartron PF, Gallenne T, Cauquil N, Le Diguarher T, Casara P, Vallette FM, Manon S, Hickman JA, Geneste O, Juin P.

Mol Cell Biol. 2011 Feb;31(4):832-44. doi: 10.1128/MCB.00161-10. Epub 2010 Dec 20.

39.

Prostaglandins antagonistically control Bax activation during apoptosis.

Lalier L, Cartron PF, Olivier C, Logé C, Bougras G, Robert JM, Oliver L, Vallette FM.

Cell Death Differ. 2011 Mar;18(3):528-37. doi: 10.1038/cdd.2010.128. Epub 2010 Oct 22.

40.

Disruption of Dnmt1/PCNA/UHRF1 interactions promotes tumorigenesis from human and mice glial cells.

Hervouet E, Lalier L, Debien E, Cheray M, Geairon A, Rogniaux H, Loussouarn D, Martin SA, Vallette FM, Cartron PF.

PLoS One. 2010 Jun 29;5(6):e11333. doi: 10.1371/journal.pone.0011333.

41.

Dnmt1/Transcription factor interactions: an alternative mechanism of DNA methylation inheritance.

Hervouet E, Vallette FM, Cartron PF.

Genes Cancer. 2010 May;1(5):434-43. doi: 10.1177/1947601910373794.

42.
43.

Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation.

Hervouet E, Vallette FM, Cartron PF.

Epigenetics. 2009 Oct 1;4(7):487-99. Epub 2009 Oct 21.

PMID:
19786833
44.

Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation.

Hervouet E, Debien E, Campion L, Charbord J, Menanteau J, Vallette FM, Cartron PF.

Clin Cancer Res. 2009 May 15;15(10):3519-29. doi: 10.1158/1078-0432.CCR-08-2062.

45.

Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members.

Gallenne T, Gautier F, Oliver L, Hervouet E, Noël B, Hickman JA, Geneste O, Cartron PF, Vallette FM, Manon S, Juin P.

J Cell Biol. 2009 Apr 20;185(2):279-90. doi: 10.1083/jcb.200809153.

46.

Bax inserts into the mitochondrial outer membrane by different mechanisms.

Cartron PF, Bellot G, Oliver L, Grandier-Vazeille X, Manon S, Vallette FM.

FEBS Lett. 2008 Sep 3;582(20):3045-51. doi: 10.1016/j.febslet.2008.07.047. Epub 2008 Aug 5.

47.

Control of Bax homodimerization by its carboxyl terminus.

Er E, Lalier L, Cartron PF, Oliver L, Vallette FM.

J Biol Chem. 2007 Aug 24;282(34):24938-47. Epub 2007 Jun 7.

48.

Bax activation and mitochondrial insertion during apoptosis.

Lalier L, Cartron PF, Juin P, Nedelkina S, Manon S, Bechinger B, Vallette FM.

Apoptosis. 2007 May;12(5):887-96. Review.

PMID:
17453158
49.

Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme.

Lalier L, Cartron PF, Pedelaborde F, Olivier C, Loussouarn D, Martin SA, Meflah K, Menanteau J, Vallette FM.

Oncogene. 2007 Jul 26;26(34):4999-5009. Epub 2007 Mar 19.

PMID:
17369862
50.

TOM22, a core component of the mitochondria outer membrane protein translocation pore, is a mitochondrial receptor for the proapoptotic protein Bax.

Bellot G, Cartron PF, Er E, Oliver L, Juin P, Armstrong LC, Bornstein P, Mihara K, Manon S, Vallette FM.

Cell Death Differ. 2007 Apr;14(4):785-94. Epub 2006 Nov 10.

Supplemental Content

Loading ...
Support Center